Decision Resources, Inc., announces the publication of Emerging Markets for Anti-Infectives, a new study that provides strategic analysis for companies marketing current anti-infective drugs and/or planning to launch new products in Argentina, Brazil, and Mexico. These nations have some of the strongest economies and largest populations in Latin America. As such, they represent burgeoning areas for investment by the pharmaceutical industry.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

This report analyzes the capacity of the health care systems of Argentina, Brazil, and Mexico in managing patients who suffer from bacterial lower respiratory tract infections (LRTIs) and hepatitis C virus (HCV) infections over a ten-year (2000-2010) forecast period. LRTIs and HCV infections have placed a heavy health care burden on these developing nations; treatments for these conditions could generate substantial revenues for drug developers.

Several factors will combine to promote sales of antibiotics for LRTIs in these emerging markets over the 2000-2010 forecast period:

  -- More aggressive switching to the more expensive third-generation      cephalosporins, fourth-generation fluoroquinolones, and newer      macrolides as first-line agents for the treatment of both bronchitis      and community-acquired pneumonia.   -- An increase in the drug-treated population due to the improvements in      public sector health services and greater pharmaceutical accessibility      for middle- and low-income patients.   -- Broader drug coverage and reimbursement programs in the private health      insurance schemes.   -- Increasing resistance to traditional antibiotics such as penicillins,      cephalosporins, and macrolides, causing a shift to more expensive and      novel therapies.  

Hepatitis C infections represent a promising area for pharmaceutical market expansion. The most significant driver of sales growth in all three markets will be the launch and widespread adoption of the pegylated interferons-Schering-Plough's Peg-Intron and Roche's Pegasys. The launch of pegylated interferons, coupled with the increasing awareness of new treatment options for hepatitis C among the general public and physicians in the emerging markets, will serve to increase in the percentage of the prevalent HCV population that is treated.

Emerging Markets for Anti-Infectives offers invaluable market intelligence for pharmaceutical companies competing in this arena. This study is part of the Infectious Disease portfolio, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or sama@dresources.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or fbidart@decisionresources.be. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X59182985

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,
sama@dresources.com

Partnerships May Yield Promising Therapies to Treat Type 2 Diabetes, According to a Decision Resources Study

View Now